Overview
Hepatobiliary and pancreatic imaging
Liver cancer (hepatocellular carcinoma)
Fatty liver, NAFLD, and NASH
Chronic liver disease and cirrhosis
Pancreatic cancer
Technical development in MRI
Quantitative imaging
Liver cancer (hepatocellular carcinoma)
Fatty liver, NAFLD, and NASH
Chronic liver disease and cirrhosis
Pancreatic cancer
Technical development in MRI
Quantitative imaging
Current Duke Appointments & Affiliations
James & Alice Chen Distinguished Professor in Radiology
·
2026 - Present
Radiology, Abdominal Imaging,
Radiology
Professor of Radiology
·
2022 - Present
Radiology, Abdominal Imaging,
Radiology
Professor in Medicine
·
2022 - Present
Medicine, Gastroenterology,
Medicine
Member of the Duke Cancer Institute
·
2016 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
CT-derived skeletal muscle predicts lung transplant approval.
Journal article JHLT Open · November 2026 BACKGROUND: Lung transplant candidate selection relies on assessment of physiologic reserve, with body mass index commonly used to guide eligibility despite its limitations in distinguishing muscle from adipose tissue. CT-derived body composition analysis ... Full text Link to item CiteSurveillance for Hepatocellular Carcinoma in Patients at High Risk.
Journal article Radiographics · October 2026 Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide and most often arises in patients with chronic liver disease and cirrhosis. Since curative treatment options are largely limited to early-stage disease, effecti ... Full text Link to item CiteRadiology considerations for the PREMIUM study: a multicenter randomized controlled trial of abbreviated MRI versus ultrasound for liver cancer screening in cirrhosis.
Journal article Abdom Radiol (NY) · September 6, 2026 This paper describes the rationale and radiology considerations in the implementation of the Preventing Liver Cancer Mortality through Imaging with Ultrasound versus MRI (PREMIUM) study. PREMIUM is a multicenter, randomized controlled trial sponsored by th ... Full text Link to item CiteRecent Grants
Evaluation of Efficacy, Safety and Tolerability of NGM282-PS-231 - NGM08
Clinical TrialPrincipal Investigator · Awarded by NGM Biopharmaceuticals, Inc. · 2024 - 2031A Phase 2a, Multicenter, Open-label, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Resmetirom in Pediatric Subjects Ages 6-17 Years with MASH with Fibrosis Stage F1-F3
Clinical TrialPrincipal Investigator · Awarded by Madrigal Pharmaceuticals, Inc. · 2026 - 2029Prospective study in human subjects that will undergo multimodality assessment of liver fat and fibrosis. Patients will be identified after undergoing clinically indicated PCCT examinations and would then be recruited for a research MR scan and US sc
Clinical TrialPrincipal Investigator · Awarded by Siemens Medical Solutions USA, Inc. · 2025 - 2029View All Grants
Education
University of Iowa ·
2004
M.D.